Lillie D. Shockney RN, BS, MAS, HON-ONN-CGUniversity Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Founder, Academy of Oncology Nurse & Patient Navigators; Co-Developer, Work Stride — Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Baltimore, Maryland
Lillie D. Shockney, RN., BS., MAS, HON-ONN-CG is well known in the cancer field, especially in navigation, survivorship, patient centered care, preservation of quality of life, end of life planning and care, improving the cancer patient’s experience and clinical outcomes. She clinically specializes in breast cancer care. Her public speaking, literary work, and notable roles she has held over the last 40+ years are well known to many.
- University Distinguished Service Professor of Breast Cancer (2016-present)
- Former Administrative Director, Johns Hopkins Breast Center (1997-2018)
- Former Director, Johns Hopkins Cancer Survivorship Programs (2011-2018)
- Professor of Surgery, Johns Hopkins University School of Medicine (2016-present)
- Co-Developer and medical advisory of Work Stride: Johns Hopkins Managing Cancer at Work Program (2012-present)
- Co-founder, the Academy of Oncology Nurse Navigators (AONN+) (2009- present)
- Former Program Director of AONN+ (2009-2019)
- Editor-in-chief of the Journal of Oncology Navigation and Survivorship (2012-present)
- Author of 20 books and > 350 articles on various cancer topics
- National and international public speaker (1997- present)
A two-time breast cancer survivor, originally diagnosed in her 30s, Lillie has worked tirelessly to improve the care of breast cancer patients around the world. She has worked at Johns Hopkins since 1983. Lillie takes great pride in the Academy of Oncology Nurse & Patient Navigators (AONN+) which as of April 2020 has more than 8,900 members. She has served as a consultant for breast cancer for national ABC News and Good Morning America, and has been also consulted regularly by the Today Show and CNN. Lillie serves on 28 medical advisory boards currently.
In 2008, The President of The Johns Hopkins University and their Board of Trustees appointed her to a Distinguished Service Faculty Chair. This is the first and only time in the history of the institution that a hospital nurse has been appointed to a distinguished service designation. She continued to climb the academic ladder and in 2016 was promoted to full professor and is the only nurse at Johns Hopkins to have a primary faculty appointment in the School of Medicine and the only nurse in the country to have reached the highest academic faculty ranking and be appointed to a faculty chair as a University Distinguished Service Professor of Breast Cancer at Johns Hopkins University School of Medicine
In 2009 she co-founded the Academy of Oncology Nurse & Patient Navigators, a national professional organization for those working in the navigation space with oncology patients.
In 2012, she and a colleague created an employee benefit called Work Stride- Managing Cancer at Work. Though originally developed for Johns Hopkins employees, its success resulted in it being offered nationally to other businesses and corporations across the country. She continues her work as a medical advisor within Johns Hopkins Healthcare Solutions to enhance the program and continue to support its growth.
She has received 61 awards—54 national awards and 7 state awards including being inducted into the Maryland Women Hall of Fame, Women in Business Healthcare Trailblazer Award, Johnson & Johnson’s Most Amazing Nurse in America award, National Komen for the Cure’s Professor of Survivorship award, and several national life time achievement awards. Her research area of focus is preservation of quality of life for patients with metastatic breast cancer.
Currently, a documentary is being made about her life and her life’s work. She tells people she never forgets where she came from—she will always be “a farmer’s daughter.”
DisclosuresLillie Shockney is on the speakers bureau for Pfizer Oncology.
Recent Contributions to PracticeUpdate:
- ASCO 2017: Abstract Recommendations From Lillie Shockney—Patient and Survivor Care
- Dasatinib With Trastuzumab and Paclitaxel Feasible in First Line for HER2-Overexpressing Advanced Breast Cancer
- Lapatinib in Combination With Foretinib in HER2-Positive Metastatic Breast Cancer
- Improved Survival of HER2-Positive MBC Patients With Newly Diagnosed vs Recurrent Disease Undergoing First-Line Trastuzumab-Based Therapy
- The Proportion of Patients With Breast Cancer Who Develop Bone Metastases
- Significance of Ki-67 Immunohistochemical Expression in Distant Metastatic Lesions in Breast Cancer
- Total Tumor Load as Intraoperative Predictor for Non–Sentinel Lymph Node Metastasis in Breast Cancer
- Eribulin in Patients With Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
- Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
- Outcomes of HER2-Positive Patients With Newly Diagnosed Stage IV or Recurrent Breast Cancer Undergoing First-Line Trastuzumab-Based Therapy